NCT06934057

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Cabozantinib and Nivolumab Among Older Patients With Renal-cell Carcinoma, a Prospective Cohort With Geriatric, Pharmacologic and Patient-reported-outcome Evaluation

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer

Detailed description

This study will be a prospective, multicentric, single-arm cohort. Patients will receive Nivolumab-Cabozantinib association per standard. All patients will benefit of geriatric evaluation (G-CODE) at inclusion, and a multimodal and reinforced follow-up, including medical oncologist, geriatrician nurse of doctor, phone calls, and optional pharmacological follow-up for Cabozantinib.

Conditions

• Kidney Cancer
• Renal Cell Cancer

Interventions

Type	Name	Description
DRUG	Nivolumab	Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
DRUG	Cabozantinib	Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.

Timeline

• Start date: 2025-05-16
• Primary completion: 2028-04-01
• Completion: 2028-04-01
• First posted: 2025-04-18
• Last updated: 2025-09-24

Locations

7 sites across 1 country: France